DexCom, Inc. (NASDAQ:DXCM) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,300 shares of the medical device company’s stock after buying an additional 248 shares during the period. GAMMA Investing LLC’s holdings in DexCom were worth $374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in DXCM. Crewe Advisors LLC acquired a new stake in DexCom in the 1st quarter valued at approximately $29,000. DSM Capital Partners LLC acquired a new stake in DexCom in the 4th quarter valued at approximately $28,000. Riverview Trust Co purchased a new position in DexCom in the 1st quarter valued at approximately $32,000. Valley National Advisers Inc. boosted its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. Finally, MV Capital Management Inc. boosted its position in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares in the company, valued at $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares in the company, valued at $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the completion of the transaction, the executive vice president now owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. Insiders sold a total of 4,135 shares of company stock worth $446,797 over the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

DXCM stock traded up $0.16 on Monday, reaching $72.46. The company had a trading volume of 9,402,596 shares, compared to its average volume of 3,637,945. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The company’s fifty day moving average is $109.33 and its 200 day moving average is $121.78. The company has a market cap of $29.04 billion, a P/E ratio of 46.65, a PEG ratio of 2.18 and a beta of 1.16. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 earnings per share. On average, research analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DXCM shares. Stifel Nicolaus decreased their price objective on shares of DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Morgan Stanley cut their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Wells Fargo & Company cut their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Royal Bank of Canada cut their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Finally, Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $111.63.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.